Compare Citius Pharmaceuticals Inc (CTXR) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Quanta Services Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Quanta Services Inc trades at $637.97 (market cap $99.18B). The key difference: Quanta Services Inc is far larger — about 6774.6× Citius Pharmaceuticals Inc's market cap, and Quanta Services Inc pays a 0.07% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PWR | |
|---|---|---|
Market Cap | $14.64M | $99.18B |
Sector | Health | Industrials |
52-Week High | $1.82 | $785.24 |
52-Week Low | $0.53 | $372.50 |
Enterprise Value | $10.86M | $105.14B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Quanta Services (PWR) trades at $646.70, down 1.8% with a bearish technical signal despite strong fundamentals. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue growth remains robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins are thin at 3.67%. Analyst consensus is strongly bullish with a $836.80 price target, representing 29% upside potential from current levels.
PWR offers exposure to infrastructure spending tailwinds from AI data centers and grid modernization, but faces valuation concerns with a P/E of 88.7. The stock's premium multiple requires flawless execution amid aggressive capital expenditure plans. Near-term technical weakness contrasts with strong institutional support and positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
